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Background: Current guidelines recommend thrombus aspiration in patients with ST-elevation myocardial
infarction (STEMI); however, there are insufficient data to unequivocally support thrombectomy in patients with
non-STEMI (NSTEMI).
Methods/Design: The TATORT-NSTEMI (Thrombus Aspiration in ThrOmbus containing culpRiT lesions in Non-ST
-Elevation Myocardial Infarction) trial is a prospective, controlled, multicenter, randomized, open-label trial enrolling
460 patients. The hypothesis is that, against a background of early revascularization, adjunctive thrombectomy leads
to less microvascular obstruction (MO) compared with conventional percutaneous coronary intervention (PCI) alone,
as assessed by cardiac magnetic resonance imaging (CMR) in patients with NSTEMI. Patients will be randomized in
a 1:1 fashion to one of the two treatment arms. The primary endpoint is the extent of late MO assessed by CMR.
Secondary endpoints include early MO, infarct size, and myocardial salvage assessed by CMR as well as enzymatic
infarct size and angiographic parameters, such as thrombolysis in myocardial infarction flow post-PCI and
myocardial blush grade. Furthermore, clinical endpoints including death, myocardial re-infarction, target vessel
revascularization, and new congestive heart failure will be recorded at 6 and 12 months. Safety will be assessed by
the incidence of bleeding and stroke.
Summary: The TATORT-NSTEMI trial has been designed to test the hypothesis that thrombectomy will improve
myocardial perfusion in patients with NSTEMI and relevant thrombus burden in the culprit vessel reperfused by
early PCI.
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Use of manual thrombectomy devices during percutan-
eous coronary intervention (PCI) in patients with acute
ST-elevation myocardial infarction (STEMI) has been
shown to decrease the incidence of cardiac death and re-
peat myocardial infarction [1-3]. Consequently, current
guidelines of the European Society of Cardiology (ESC)
and the American Heart Association/American College
of Cardiology (AHA/ACC) recommend manual thromb-
ectomy in patients with STEMI (class IIa, level of evi-
dence A, and class IIa, level of evidence B, respectively)
[4,5]. However, approximately 50 to 70% of all patients
with non-ST-elevation myocardial infarction (NSTEMI)
also display a relevant thrombus burden in the culprit
vessel [6,7]. Furthermore, with rates of angiographic no-
reflow phenomenon ranging from 15 to 40%, depending
on thrombus burden and intra-procedural thrombotic
events, only suboptimal reperfusion success can be
achieved in a significant portion of patients with
NSTEMI [8-10]. Thus, thrombectomy in patients with
NSTEMI may represent a useful intervention, with the
potential to improve patient prognosis. However, current
guidelines do not give a clear recommendation for
thrombus aspiration in NSTEMI [11,12]. This is mainly
because of the lack of data on thrombus aspiration in
NSTEMI, as only one small prospective observational
study has been published to date [7]; in that 70-patient
study, thrombectomy had a similar effectiveness rate to
that reported in patients with STEMI.
This emphasizes the need for an adequately
powered randomized controlled trial (RCT) to
address the current role of thrombus aspiration in
patients with NSTEMI and a relevant thrombus
burden in the culprit vessel. The TATORT-NSTEMI
(Thrombus Aspiration in ThrOmbus containing
culpRiT lesions in Non-ST-Elevation Myocardial
Infarction) trial is designed to test the hypothesis
that against a background of early revascularization,
adjunctive thrombectomy leads to less microvascular
obstruction (MO) compared with conventional PCI
alone, as assessed by cardiac magnetic resonance
imaging (CMR).
Methods/design
The TATORT-NSTEMI trial is a prospective, multi-
center, randomized, controlled, open-label study to
compare PCI plus routine thrombus aspiration with
PCI without thrombus aspiration in patients with
NSTEMI and relevant thrombus burden who are
undergoing early invasive reperfusion therapy. The
study will determine if adjunctive thrombectomy is
superior than PCI alone with respect to the extent of
no-reflow/MO assessed by CMR in patients with
NSTEMI.Primary and secondary endpoints
The primary study endpoint of the TATORT-NSTEMI
trial is the extent of late MO assessed by CMR on days 1
to 4 after randomization. Using CMR, zones of MO
within the infarcted myocardium can be visualized and
quantified, representing the CMR equivalent of the no-
reflow phenomenon [13,14]. MO assessed by CMR has
not only been shown to be associated with adverse func-
tional outcome after myocardial infarction [15,16], but
also with adverse clinical outcome including mortality
[17-19]. Further, late MO assessed 15 minutes after
contrast-medium injection has been shown to have
higher prognostic impact than early MO assessed 1 to 2
minutes after gadolinium administration or by first-pass
gadolinium-enhanced perfusion [17,20]. The mechanistic
hypothesis of the current trial is that thrombus aspir-
ation will result in reduction of distal embolization, thus
preserving microvascular integrity, reflected by less late
MO, which will translate into improved clinical
outcome.
Secondary endpoints include other CMR parameters
associated with patient prognosis, such as early MO, in-
farct size, myocardial salvage, and left ventricular ejec-
tion fraction (LVEF), as well as angiographic markers of
reperfusion success such as the thrombolysis in myocar-
dial infarction (TIMI) flow post-PCI and myocardial
blush grade [18,21]. In addition, troponin T after 24 and
48 hours for determination of enzymatic infarct size will
be evaluated. Further, a combined clinical endpoint in-
cluding death, re-infarction, target vessel revasculariza-
tion, and congestive heart failure (CHF) will be assessed
after 6 and 12 months. Death is defined as death from
any cause, but will be divided into cardiac and non-
cardiac causes, and will be regarded as cardiac in origin
unless obvious non-cardiac causes can be identified.
The diagnosis of re-infarction during the index
hospitalization will be based on clinical symptoms,
new ST-segment changes, and an increase in the
creatine kinase-MB levels above the reference limits
in patients with normalized values, or if there is an
increase of more than 20% from the most recent
non-normalized measurement. At follow-up, any new
ischemic symptoms leading to hospital admission
accompanied by raised troponin levels will be defined
as re-infarction [22]. New CHF after randomization
during hospital stay will be defined as CHF when
there is at least one of the following conditions and it
requires treatment with diuretics (cardiogenic shock,
pulmonary edema, or signs of pulmonary congestion
on X-ray, rales of greater than one-third from lung
basis, pulmonary capillary wedge pressure >25 mmHg,
or dyspnea with blood oxygen saturation <90% in the
absence of lung disease). After hospital discharge, any
new CHF leading to re-hospitalization will be counted.
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at 6 and 12 months. Any clinical event will be verified by
hospital or general practitioner records. Finally, assess-
ment of quality of life will be performed using the
EuroQol-5D (www.euroqol.org) questionnaire during the
6-month and 12-month follow-ups.
Safety assessment will include stroke and bleeding
until hospital discharge. Stroke will be defined as any
new neurological symptoms in association with signs ofFigure 1 Study flow chart. CMR, cardiac magnetic resonance; NSTEMI, no
intervention; TIMI, thrombolysis in myocardial infarction.ischemia or hemorrhage in cranial computed tomog-
raphy or magnetic resonance imaging. Bleeding will be
defined in accordance with the GUSTO (Global
Utilization of Streptokinase and t-PA for Occluded Cor-
onary Arteries) criteria as 1) severe or life-threatening,
2) moderate, or 3) mild bleeding [23]. However, based
on previous studies, thrombus aspiration is associated
with only modest complications, therefore no major
safety concern for thrombus aspiration is expected. Alln-ST-elevation myocardial infarction; PCI, percutaneous coronary
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toring Board (DSMB). All clinical and safety endpoints
will be adjudicated by a Clinical Endpoints Committee
(CEC) blinded to treatment assignment, based on data
provided by the clinical-trial sites.
Patient population
The study population will consist of 460 patients with
NSTEMI enrolled at eight centers in Germany. Informed
consent will be required prior to randomization.
Patients will be eligible for the study if they have: 1) is-
chemic symptoms such as angina pectoris for more than
20 minutes; 2) occurrence of previous symptoms less
than 72 hours before randomization; 3) cardiac troponin
levels above the 99th percentile; and 4) culprit lesion
containing thrombus (TIMI thrombus grade 2 to 5
within the lesion) and intended early PCI.
Exclusion criteria will be presence of cardiogenic
shock, STEMI, no identifiable culprit lesion, coronary
morphology ineligible for thrombectomy (for example,
very tortuous vessels or severe calcification), indication
for acute bypass surgery, age less than 18 or more than
90 years, pregnancy, current participation in another
clinical study, co-morbidity with limited life expectancy
of less than 6 months or contraindications to CMR at
study entry (for example, severe claustrophobia, im-
planted pacemakers or defibrillators, relevant metallic
implants, known allergy to gadolinium, severe renal fail-
ure with creatinine clearance <30 ml/h), and contraindi-
cations for treatment with heparin, aspirin, or
thienopyridines.
Randomization and patient treatment
Patient randomization will be performed centrally, with
a randomization ratio of 1:1 (n = 230 patients per group;
see Figure 1 for study flow) using an internet-based
randomization program. No stratification will be
performed. All participating hospitals are high-volume
tertiary care centers with experienced cardiologists
performing all interventions. Manual thrombectomy will
be performed in the thrombus aspiration group with an
aspiration catheter commonly used in daily clinical rou-
tine (Eliminate®; Terumo Europe, Leuven, Belgium). In
the standard PCI group, patients will be treated by con-
ventional PCI in accordance with local practice without
thrombectomy. Cross-over is not planned; however, if
this occurs, the reasons will be recorded. Manual
thrombectomy will be the only difference between the
groups, and all other therapeutic procedures will be
similar in both treatment arms.
In vessels with a diameter of greater or equal than 2.5
mm, stent implantation is recommended. In both
groups, the decision whether to use bare-metal or drug-
eluting stents or whether to use glycoprotein IIb/IIIainhibitors will be left to the discretion of the interven-
tional cardiologist and the treatment decided upon will
be recorded. Anticoagulant therapy including adminis-
tration of heparin, bivalirudin, or low-molecular-weight
heparin will be carried out in accordance with standard
clinical practice and current guidelines. Additional treat-
ment of other stenoses will be carried out if the inter-
ventional cardiologist deems it advisable, and will be
recorded. Concomitant drug therapy for the treatment
of NSTEMI will be administered based on the decision
of the individual investigator and the common practice
of the participating hospitals, in accordance with current
guidelines. Anti-platelet therapy with initial loading dose
will consist of aspirin 100 mg per day in combination
with prasugrel 60 mg loading dose and subsequently 10
mg for 12 months for patients without contraindication
to prasugrel. Patients pre-treated with clopidogrel should
be switched to prasugrel whereas patients pre-treated
with ticagrelor will not be switched. Post-infarction
treatment includes administration of angiotensin-
converting enzyme inhibitors or angiotensin-II-receptor
antagonists, beta-blockers, and statins [11,12].
Cardiac magnetic resonance image acquisition
The primary endpoint (late MO) and secondary end-
points such as early MO, infarct size, and myocardial
salvage will be assessed by CMR performed on a 1.5 or
3.0 Tesla scanner. Imaging will be performed on days 1
to 4 after randomization, using a standard scanning
protocol (Figure 2). In brief, late MO and infarct size
will be assessed in delayed enhancement short-axis im-
ages covering the whole ventricle acquired at mid-
diastole approximately 15 minutes after bolus injection
(0.2 mmol/kg bodyweight) of gadobutrol (Gadovist,
Schering, Germany). An inversion recovery (IR) turbo
gradient echo sequence will be used for image acquisi-
tion. The individual IR pre-pulse delay will be defined to
obtain the maximal contrast between viable and necrotic
myocardium. Early MO will be assessed 1 to 2 minutes
after contrast-medium injection. For determination of
edema/area at risk, short-axis slices covering the entire
left ventricle (LV) before contrast administration will be
obtained using a T2-weighted triple IR turbo spin-echo
sequence. Assessment of LV function and volumes will
be performed using a standard steady-state free preces-
sion technique, acquiring short-axis slices from base to
apex and also horizontal and vertical long-axis views.
Late and early MO, infarct size and area at risk will be
expressed as percentages of the left ventricular mass (%
LV), given by the sum of the mass of late and early MO
regions, late enhancement and edema for all slices di-
vided by the sum of the LV myocardial cross-sectional
mass. The myocardial salvage index will be calculated as
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Figure 2 Cardiac magnetic resonance imaging scan protocol. Flip, flip angle; IR, inversion recovery; SSFP, steady-state free precession; STIR,
short tau inversion recovery; repetition time; TE, echo time.
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from the short-axis functional views. The scan protocol
and image analysis will be standardized at all sites and
have been used effectively in previous studies [25-27]. All
participating centers are experienced in using this type of
conducted scan. CMR images will be sent to the CMR core
laboratory at the University of Leipzig – Heart Center,
Germany. The CMR core laboratory is highly experienced,
has excellent reproducibility and low inter-observer and
intra-observer variability for infarct size and myocardial
salvage assessment, and has previously served as a core la-
boratory in studies of acute coronary syndromes [25-27].
Image analysis for the assessment of early and late MO,
area at risk and infarct size, and total LV mass and volumes
using a semi-automatic approach will be performed in
anonymized form by blinded operators.
Assessment of secondary angiographic endpoints
Both before and after PCI, the culprit vessel should be vi-
sualized in several projections in order to obtain particu-
larly precise display of the distal segments. Evaluation of
thrombus burden will be performed before and after PCI,
in accordance with the TIMI thrombus grade scale.The flow within the infarct-related artery will be
assessed using the TIMI criteria and the corresponding
myocardial blush grades [28,29]. For the assessment of
myocardial blush, it is especially important for the inves-
tigators to provide film material with a sufficiently long
duration to allow evaluation of myocardial perfusion. A
central blinded analysis for TIMI flow, blush grade, and
thrombus burden will be performed at the angiographic
core lab of the University of Saarland.Biomarker sub-study
In a single-center sub-study (University Leipzig – Heart
Center, Germany) blood will be collected from the fem-
oral sheath (peripheral blood) and from the infarct-
related coronary artery for biomarker sub-studies for ap-
proximately 200 patients. In this technique, the plasma
is separated by centrifugation at 3500 g for 10 minutes,
and aliquots are stored at −80°C until used. Multiple
biomarkers such as markers of CHF, inflammation, or
myocardial-derived microRNAs (miRNAs) will be ana-
lyzed. In addition, assessment of platelet function will be
performed.
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In a two-center study (University of Leipzig - Heart
Center and University of Tübingen, both in Germany)
that will include approximately 100 patients, the com-
position and key determinants of aspirated thrombi
will be analyzed. This will include histological and
immunohistological analysis, and analysis of specific
biomarkers such as thrombus miRNAs. The probes
will be stored at −80°C and transferred to the core facility
at the University of Tübingen.
Data and statistical analysis
The aim of the study is to demonstrate superiority of
manual thrombus aspiration versus standard PCI with-
out thrombus aspiration, based on the primary endpoint
of late MO in the study patients.
At the time of planning the study, the only available
data on MO in NSTEMI were from a study on a small
number (n = 25) of patients [30]. Thus, we initially
based our sample-size calculation on previous in-house
studies of the University of Leipzig - Heart Center in pa-
tients with STEMI and NSTEMI. An absolute difference
in the primary endpoint (late MO) of 1.0%LV between
the two treatment groups was expected, and a standard
deviation of 3.3%LV was assumed [17,26,27,31]. Based
on α = 5%, a two-sided hypothesis test, and a statistical
power of 80%, 172 patients per group would be needed
to reject the null hypothesis of no difference between
groups.
In the intervening time, two other studies on MO and
NSTEMI were published, which reported a lower preva-
lence and extent of MO than expected [20,32]. Thus, the
Steering Committee decided to perform a preliminary
analysis on CMR parameters, including the first 60
patients enrolled in TATORT-NSTEMI. A prevalence of
MO of approximately 40% with a median extent of
1.0%LV was oberserved. We thus decided to critically re-
vise our sample-size calculation and adapt it based on
the new available data and the preliminary analysis. We
now expect an absolute difference in the primary end-
point (late MO) of 0.5%LV between the two treatment
groups with a mean extent of 1.0%LV for late MO in the
whole study cohort [20,32]. This difference is judged as
clinically relevant [17,20,26,27,31]. A standard deviation
of 1.8%LV is assumed [17,20,26,27,31,32]. Based on α =
5%, a two-sided hypothesis test, and a statistical power
of 80%, 204 patients per group are needed to reject the
null hypothesis of no difference between groups. On the
basis of clinical experience and data in STEMI, it is fur-
ther expected that it will not be possible to perform
thrombectomy for 5% of all patients in the thrombec-
tomy group, and that 10% of all patients, either will not
undergo a CMR examination or their CMR images will
be of insufficient quality for analysis [17,26,27]. This willresult in a sample size of 2 × 230 randomized patients
per group. We thus decided to include 60 additional pa-
tients after critical revision and adaptation of our initial
sample-size calculation. This protocol modification was
approved by the central ethics committee at the Univer-
sity of Leipzig. Sample-size calculation was performed
using SigmaStat software (Version 3.5; Systat Software
Inc., Chicago, IL, USA).
Pre-specified subgroup analyses by gender, presence of
diabetes, TIMI thrombus burden (2 to 4 versus 5), TIMI
flow pre-PCI (0 to 1 versus 2 to 3), and time from most
recent symptoms to occurrence of PCI (<6 versus ≥6
hours), and additional administration of glycoprotein
IIb/IIIa inhibitors will be performed.
All patients will be analyzed on an intention-to-treat
basis. The differences in primary and secondary end-
points between the treatment groups will be assessed
using an unpaired t-test. In addition, as a secondary ana-
lysis, the differences between the treatment groups in
the main outcome will be assessed using an unpaired t-
test adjusted by baseline values (ANCOVA). Categorical
variables will be analyzed by Fisher’s exact test. The 95%
confidence interval (CI) for differences in quantitative
data will be displayed. For clinical events, relative risks
and 95% CI will be reported. To identify factors associ-
ated with the observed results, univariate and multivari-
ate regression analysis will be performed. To assess
clinical outcome, Kaplan-Meier curves with log-rank
comparison and Cox regression analyses will be
performed. A two-tailed P-value of <0.05 will be consid-
ered significant.
Study organization
The TATORT-NSTEMI Steering Committee is chaired
by Prof. Dr. Holger Thiele (University of Leipzig – Heart
Center, Leipzig, Germany), co-chaired by Prof. Dr.
Uwe Zeymer, (Institut für Herzinfarktforschung [IHF],
Ludwigshafen, Germany), and Prof. Dr. Bruno Scheller
(University of Saarland, Campus Homburg/Saar, Homburg,
Germany). The Steering Committee is responsible for
the scientific content of the protocol and oversees the
trial operations, and will perform the preparation of the
primary manuscript and other publications arising from
the TATORT-NSTEMI trial. Each participating center
has a coordinator with extensive clinical-trial experience.
All trial-related processes will follow the standard oper-
ating procedures of the IHF, which is an independent
clinical-research organization providing biometry, study
coordination, monitoring, and data management. Cen-
tral monitoring will include a timely query-management
process based on consistency and plausibility checks
automatically generated from the database, combined
with a dunning process for missing documentation and
a reminder system in advance for upcoming visits. On-
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close-out. During recruitment and follow-up, all centers
will be visited regularly to check adherence to good clin-
ical practice and trial protocol. The focus of the visits
will be on the verification of informed-consent docu-
ments, eligibility criteria, key primary and secondary
endpoints, and safety aspects.
The trial will be monitored by an independent DSMB.
The CEC will adjudicate all clinical endpoints. The trial
follows a standard study organization with a Steering
Committee, DSMB, and CEC.
The study has been approved by the central ethical
committee at the University of Leipzig and at all local
ethics committees at the participating sites.
Discussion
Despite early invasive strategies and optimal medical
treatment, morbidity and mortality rates for NSTEMI
and STEMI continue to be high. Thus, further improve-
ment of the initial therapy is necessary to improve patient
outcome. The pivotal TAPAS (Thrombus Aspiration dur-
ing Percutaneous coronary intervention in Acute myo-
cardial infarction Study) trial of patients with STEMI,
which compared a strategy with thrombectomy with a
strategy without thrombectomy, showed a reduction
in cardiac mortality at 1 year [1]. By contrast, other ran-
domized, controlled studies did not observe superiority of
thrombectomy over standard PCI with respect to surrogate
endpoints of reperfusion success [33,34]. However, meta-
analyses in patients with STEMI showed a mortality-related
benefit after thrombectomy compared with PCI alone
[2,3]. Therefore, the current guidelines of the ESC
on revascularization therapy in patients with STEMI
reperfused by primary PCI have increased the recommen-
dation class for manual thrombectomy from the previous
class IIb, level of evidence B to class IIa, level of evidence
A [4]. In line with the ESC guidelines, thrombectomy
is strongly recommended by the AHA/ACC guidelines
(class IIa, level of evidence B) [5].
Notably, in the majority of both STEMI and NSTEMI
cases, the key pathophysiological substrate is rupture of
a vulnerable plaque with subsequent coronary throm-
bosis. Whereas in STEMI the thrombus is mostly fibrin-
rich leading to total vessel occlusion, the thrombus in
many patients with NSTEMI is predominantly platelet-
rich and unstable. leading to partial or intermittent oc-
clusion of the coronary vessel [35]. The majority of
patients with NSTEMI display relevant thrombus burden
and thus might benefit from thrombectomy [6,7]; how-
ever, current guidelines do not recommend thrombus
aspiration in patients with NSTEMI [11,12]. This is
mainly because of the lack of data for patients with
NSTEMI, with only one published prospective observa-
tional study to date [7]. In that study, which enrolled 70patients with NSTEMI, a thrombus was detected by the
initial angiogram in approximately 50% of participants.
No complications occurred during thrombectomy. Man-
ual thrombus aspiration was associated with a significant
reduction of the TIMI thrombus score (score 4/5 in 40%
of patients before thrombectomy versus 7% after throm-
bectomy) and an increase in the rate of TIMI flow 3 (in
36% pre-thrombectomy versus 66% post-thrombectomy).
After thrombus aspiration, direct stenting without pre-
dilatation was possible in 39 patients (55.7%). Thus, this
study showed that thrombus aspiration in patients with
NSTEMI is feasible, effective, and safe.
However, RCTs are necessary to investigate whether
thrombus aspiration in NSTEMI results in improved
angiographic, functional, and clinical outcomes com-
pared with conventional PCI. Currently, one additional
randomized single-center study comparing thrombec-
tomy with PCI alone is ongoing (TAPAS-II study) [36].
The primary endpoint of that study is myocardial blush
grade, and the study aims to enroll 560 patients with
NSTEMI. The main limitations of that study are its
single-center design and the performance of unselected
thrombectomy in all patients, independent of thrombus
presence. In addition, the primary endpoint of myocar-
dial blush grade is only an indirect marker for myocar-
dial perfusion. By contrast, the primary endpoint of our
proposed study, late MO by CMR, allows direct
visualization and quantification of no-reflow and micro-
circulatory impairment [15,16]. Both myocardial blush
and MO are surrogate endpoints, and evidently assessing
clinical outcome as primary endpoint would lead to
more robust data. However, late MO has been shown to
be a strong independent predictor for clinical outcome,
including mortality, after acute coronary syndromes
[17-19]. The main pathophysiological mechanism for the
development of MO is distal embolization [13,14]. Be-
cause manual thrombus removal reduces thrombus bur-
den and thereby distal embolization, the primary
endpoint of the current trial (MO) and the studied inter-
vention (manual thrombectomy) are directly and caus-
ally linked with each other on a pathophysiological basis.
Previous data for patients with STEMI indicate that in
approximately 10% of all patients the thrombus aspir-
ation catheter fails to cross the lesion [37]. Because le-
sions in NSTEMI are often less complex and frequently
display lower-grade stenoses, it can be expected that it
will not be possible to perform thrombectomy in a
smaller percentage (approximately 5%) of all patients in
the thrombectomy group. To reduce the rate of unsuc-
cessful thrombectomy, presence of a coronary morph-
ology ineligible for thrombectomy (for example, patients
with very tortuous vessels or severe calcification) will be
a primary exclusion criterion. In addition, only interven-
tional cardiologists experienced in manual thrombectomy
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possible as a result of the intervention used. However, sev-
eral methods to restrict bias will be implemented, such as
a central computerized randomization system; a blinded
CEC to assess all relevant clinical events; a blinded CMR
and angiographic core laboratory; and high standard re-
quirements concerning the clinical level and experience of
centers and investigators in terms of numbers of PCIs
performed, cases of NSTEMI treated, and participation in
cardiologic clinical trials.
In clinical trials using CMR parameters as surrogate
endpoints, the time period for CMR image acquisition
after the index event or randomization is of importance
for the final quality and reproducibility of the results.
However, previous studies analyzing the influence of
timing of CMR image acquisition on CMR parameters
led to inconsistent results. In contrast to previously pub-
lished animal data with stable infarct size and MO mea-
surements between day 2 and 7 after the index event
[38],there has been increasing evidence recently based
on findings in humans that infarct size decreases within
the first week after the initial event [39-42]. However,
these studies included only small study sample sizes, and
to date, the precise devolution of the infarcted areal
within the first days has not been investigated. Thus,
based on current data and practicability of perform-
ance of CMR within clinical routine times to assure
high-quality image acquisition, we chose to acquire
CMR images within the narrow time period of 1 to 4
days after randomization. Furthermore, we do not
expect differences in timing of CMR in both treatment
groups. Thus, even if there were to be an increase or
decrease in MO over time in humans, this would not
affect the study results.
Trial status
Recruitment began in March 2011 and of December
2012, almost 360 patients had been enrolled. Given these
inclusion rates, completion of enrollment is expected by
July 2013. It is expected that complete data will be avail-
able in September 2013.
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